Immunotherapy based on immune checkpoint blockers has shown great therapeutic potential by blocking the interaction between checkpoint receptors on immune cells and their ligands on tumor cells, thereby restoring T cell functionRead More…
Whole-genome doubling (WGD) is a recurring event in human cancer that promotes chromosomal instability and the acquisition of aneuploidy, but the three-dimensional (3D) assembly of chromatin in WGD cells and its contributionRead More…
Pfizer announced that the U.S. Food and Drug Administration (FDA) has granted priority review status to its biologics license application (BLA) for elranatamab, an anti-CD3/BCMA bispecific antibody (bsAb), with a decision onRead More…
A kind of chronic leukemia, myeloproliferative neoplasms (MPNs), can afflict patients for many years and some patients may require treatment to better manage this type of blood cancer, while others may experienceRead More…
Preventing cancer metastasis remains one of the main goals of current research, as most malignant cells can metastasize by exploiting abnormal leakage from blood vessels. In a recent study published in theRead More…
Bispecific antibodies, with two binding sites directed at two different antigens or two different epitopes on the same antigen, have shown some superiority in clinical therapeutic effects when compared with monoclonal antibodies,Read More…
Neovascular age-related macular degeneration (nAMD ) and diabetic macular edema (DME) are retinal diseases that are the two leading causes of vision loss, affecting more than 40 million people worldwide. Roche recentlyRead More…
The 10th Annual Immuno-Oncology Summit was held in Boston during October 12-14, 2022. Creative Biolabs, as an exhibitor, successfully showcased at the 10th Annual Immuno-Oncology Summit at booth #9 and has attractedRead More…
With more clinical candidates and commercial success than ever within this rapidly developing space, multi-specifics is evidently the fourth wave of drug discovery. With more clinical candidates and commercial success than everRead More…
Antibody fragmentation and/or disulfide bond (DSB) reduction are common phenomena in antibody production processes, mainly caused by non-enzymatic (environmental) factors and enzymatic catalysis. Compared with traditional monoclonal antibodies (mAbs), bispecific antibodies (bsAbs)Read More…